FMP
Odonate Therapeutics, Inc.
ODT
NASDAQ
Inactive Equity
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
1.12 USD
-0.04999995 (-4.46%)
About
ceo
Mr. Kevin Tang
sector
Healthcare
industry
Biotechnology
website
https://www.odonate.com
exchange
NASDAQ
Description
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
CIK
0001717452
ISIN
N/A
CUSIP
N/A
Address
4747 Executive Dr Ste 510
Phone
18582003830
Country
US
Employee
137
IPO Date
Dec 7, 2017
Key Executives
